» Articles » PMID: 38001632

Recent Progress in Enhanced Cancer Diagnosis, Prognosis, and Monitoring Using a Combined Analysis of the Number of Circulating Tumor Cells (CTCs) and Other Clinical Parameters

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001632
Authors
Affiliations
Soon will be listed here.
Abstract

Analysis of circulating tumor cells (CTCs) holds promise to diagnose cancer or monitor its development. Among the methods, counting CTC numbers in blood samples could be the simplest way to implement it. Nevertheless, its clinical utility has not yet been fully accepted. The reasons could be due to the rarity and heterogeneity of CTCs in blood samples that could lead to misleading results from assays only based on single CTC counts. To address this issue, a feasible direction is to combine the CTC counts with other clinical data for analysis. Recent studies have demonstrated the use of this new strategy for early detection and prognosis evaluation of cancers, or even for the distinguishment of cancers with different stages. Overall, this approach could pave a new path to improve the technical problems in the clinical applications of CTC counting techniques. In this review, the information relevant to CTCs, including their characteristics, clinical use of CTC counting, and technologies for CTC enrichment, were first introduced. This was followed by discussing the challenges and new perspectives of CTC counting techniques for clinical applications. Finally, the advantages and the recent progress in combining CTC counts with other clinical parameters for clinical applications have been discussed.

Citing Articles

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


A Preliminary Analysis of Circulating Tumor Microemboli from Breast Cancer Patients during Follow-Up Visits.

Lai H, Huang H, Hao Y, Lee H, Wang C, Ling T Curr Oncol. 2024; 31(9):5677-5693.

PMID: 39330049 PMC: 11431662. DOI: 10.3390/curroncol31090421.


Recent advances in minimally invasive biomarkers of OSCC: from generalized to personalized approach.

Suri S, Boora G, Kaur R, Chauhan A, Ghoshal S, Pal A Front Oral Health. 2024; 5:1426507.

PMID: 39157206 PMC: 11327221. DOI: 10.3389/froh.2024.1426507.


A Novel Method for the Early Detection of Single Circulating, Metastatic and Self-Seeding Cancer Cells in Orthotopic Breast Cancer Mouse Models.

Murad M, Chen Y, Iaria J, Fonseca Teixeira A, Zhu H Cells. 2024; 13(14.

PMID: 39056749 PMC: 11275056. DOI: 10.3390/cells13141166.


Current Applications and Future Directions of Circulating Tumor Cells in Colorectal Cancer Recurrence.

Tsai K, Huang P, Chu P, Nguyen T, Hung H, Hsieh C Cancers (Basel). 2024; 16(13).

PMID: 39001379 PMC: 11240518. DOI: 10.3390/cancers16132316.


References
1.
Cristofanilli M, Budd G, Ellis M, Stopeck A, Matera J, Miller M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8):781-91. DOI: 10.1056/NEJMoa040766. View

2.
Kallergi G, Politaki E, Alkahtani S, Stournaras C, Georgoulias V . Evaluation of Isolation Methods for Circulating Tumor Cells (CTCs). Cell Physiol Biochem. 2016; 40(3-4):411-419. DOI: 10.1159/000452556. View

3.
Pore A, Bithi S, Zeinali M, Navaid H, Nagrath S, Layeequr Rahman R . Phenotyping of rare circulating cells in the blood of non-metastatic breast cancer patients using microfluidic Labyrinth technology. Biomicrofluidics. 2022; 16(6):064107. PMC: 9759355. DOI: 10.1063/5.0129602. View

4.
Kallergi G, Papadaki M, Politaki E, Mavroudis D, Georgoulias V, Agelaki S . Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients. Breast Cancer Res. 2011; 13(3):R59. PMC: 3218948. DOI: 10.1186/bcr2896. View

5.
Meyerhardt J, Mangu P, Flynn P, Korde L, Loprinzi C, Minsky B . Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2013; 31(35):4465-70. DOI: 10.1200/JCO.2013.50.7442. View